Association between the SLCO1B1 polymorphisms and the risk of anti-tuberculosis drug-induced liver injury
| Polymorphism | Genetic model | Number of studies | OR (95% CI) | P value | I2, % | P heterogeneity | Model of meta-analysis | |
|
SLCO1B1
388A>G (rs2306283) | Dominant model | AA+AG vs GG | 4 | 1.00 (0.76 to 1.31) | 1.00 | 0 | 0.73 | Fixed |
| Recessive model | AA vs AG+GG | 4 | 1.45 (0.93 to 2.25) | 0.10 | 0 | 0.84 | Fixed | |
| Additive model | AA vs GG | 4 | 1.36 (0.85 to 2.15) | 0.20 | 0 | 0.98 | Fixed | |
|
SLCO1B1 521T>C
(rs4149056) | Dominant model | CC+TC vs TT | 4 | 0.74 (0.43 to 1.28) | 0.28 | 66 | 0.03 | Random |
| Recessive model | CC vs TC+TT | 4 | 1.21 (0.40 to 3.64) | 0.73 | 0 | 0.57 | Fixed | |
| Additive model | CC vs TT | 4 | 1.27 (0.42 to 3.84) | 0.67 | 0 | 0.61 | Fixed | |
SLCO1B1, solute carrier organic anion transporter family member 1B1.